• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重症监护病房中的肾脏替代治疗。

Renal replacement therapy in ICU.

作者信息

Deepa C, Muralidhar K

机构信息

Narayana Hrudayalaya, Bangalore, Karnataka, India.

出版信息

J Anaesthesiol Clin Pharmacol. 2012 Jul;28(3):386-96. doi: 10.4103/0970-9185.98357.

DOI:10.4103/0970-9185.98357
PMID:22869954
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3409957/
Abstract

Diagnosing and managing critically ill patients with renal dysfunction is a part of the daily routine of an intensivist. Acute kidney insufficiency substantially contributes to the morbidity and mortality of critically ill patients. Renal replacement therapy (RRT) not only does play a significant role in the treatment of patients with renal failure, acute as well as chronic, but also has spread its domains to the treatment of many other disease conditions such as myaesthenia gravis, septic shock and acute on chronic liver failure. This article briefly outlines the role of renal replacement therapy in ICU.

摘要

诊断和管理肾功能不全的重症患者是重症监护医生日常工作的一部分。急性肾功能不全是重症患者发病和死亡的重要原因。肾脏替代治疗(RRT)不仅在急慢性肾衰竭患者的治疗中发挥着重要作用,而且其应用领域已扩展到许多其他疾病的治疗,如重症肌无力、感染性休克和慢性肝功能衰竭急性发作。本文简要概述了肾脏替代治疗在重症监护病房中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d00/3409957/8362fad313d2/JOACP-28-386-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d00/3409957/5b0540a0135c/JOACP-28-386-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d00/3409957/378a571b2165/JOACP-28-386-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d00/3409957/8362fad313d2/JOACP-28-386-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d00/3409957/5b0540a0135c/JOACP-28-386-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d00/3409957/378a571b2165/JOACP-28-386-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d00/3409957/8362fad313d2/JOACP-28-386-g005.jpg

相似文献

1
Renal replacement therapy in ICU.重症监护病房中的肾脏替代治疗。
J Anaesthesiol Clin Pharmacol. 2012 Jul;28(3):386-96. doi: 10.4103/0970-9185.98357.
2
Single-best Choice Between Intermittent Versus Continuous Renal Replacement Therapy: A Review.间歇性与连续性肾脏替代治疗的最佳单一选择:综述
Cureus. 2019 Sep 3;11(9):e5558. doi: 10.7759/cureus.5558.
3
Sustained low-efficiency daily diafiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy: towards an adequate therapy.适用于需要肾脏替代治疗的危重症患者的持续低效每日透析滤过(SLEDD-f):迈向充分治疗
Nephrol Dial Transplant. 2004 Apr;19(4):877-84. doi: 10.1093/ndt/gfg625.
4
New experiences with the therapy of acute kidney injury.急性肾损伤治疗的新经验。
Prilozi. 2008 Dec;29(2):119-53.
5
Intermittent hemodialysis versus continuous renal replacement therapy for acute renal failure in the intensive care unit: an observational outcomes analysis.重症监护病房中急性肾衰竭患者间歇性血液透析与连续性肾脏替代治疗的疗效观察分析
J Intensive Care Med. 2008 May-Jun;23(3):195-203. doi: 10.1177/0885066608315743.
6
Effects of dialysis modality on blood loss, bleeding complications and transfusion requirements in critically ill patients with dialysis-dependent acute renal failure.透析方式对依赖透析的急性肾衰竭危重症患者失血、出血并发症及输血需求的影响
Anaesth Intensive Care. 2015 Nov;43(6):764-70. doi: 10.1177/0310057X1504300615.
7
Accelerated versus standard initiation of renal replacement therapy for critically ill patients with acute kidney injury: a systematic review and meta-analysis of RCT studies.加速与标准起始肾脏替代治疗对急性肾损伤危重症患者的影响:一项 RCT 研究的系统评价和荟萃分析。
Crit Care. 2021 Jan 5;25(1):5. doi: 10.1186/s13054-020-03434-z.
8
Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.接受肾脏替代治疗患者抗菌治疗的药代动力学考量
Clin Pharmacokinet. 2007;46(12):997-1038. doi: 10.2165/00003088-200746120-00003.
9
Continuous renal replacement therapy improves renal recovery from acute renal failure.连续性肾脏替代疗法可改善急性肾衰竭患者的肾脏恢复情况。
Can J Anaesth. 2005 Mar;52(3):327-32. doi: 10.1007/BF03016071.
10
Renal replacement therapy in the ICU: intermittent hemodialysis, sustained low-efficiency dialysis or continuous renal replacement therapy?重症监护病房中的肾脏替代治疗:间歇性血液透析、持续低效透析或连续性肾脏替代治疗?
Curr Opin Crit Care. 2018 Dec;24(6):437-442. doi: 10.1097/MCC.0000000000000541.

引用本文的文献

1
Efficacy of Regional Citrate versus Heparin Anticoagulation in Continuous Renal Replacement Therapy.局部枸橼酸盐与肝素抗凝在连续性肾脏替代治疗中的疗效比较
Indian J Nephrol. 2025 May-Jun;35(3):380-384. doi: 10.25259/ijn_195_23. Epub 2024 Aug 1.
2
assessment and simulation to guide cefepime-taniborbactam dosing recommendations for patients receiving continuous renal replacement therapy.评估与模拟,以指导接受连续性肾脏替代治疗的患者使用头孢吡肟-他尼硼巴坦的给药建议。
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0006125. doi: 10.1128/aac.00061-25. Epub 2025 May 5.
3
assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations.

本文引用的文献

1
Effects of reducing the lactate and glucose content of PD solutions on the peritoneum. Is the future GLAD?降低腹膜透析液中乳酸盐和葡萄糖含量对腹膜的影响。未来会是葡萄糖乳酸盐替代透析液(GLAD)吗?
NDT Plus. 2008 Oct;1(Suppl 4):iv56-iv62. doi: 10.1093/ndtplus/sfn126.
2
An Official ATS/ERS/ESICM/SCCM/SRLF Statement: Prevention and Management of Acute Renal Failure in the ICU Patient: an international consensus conference in intensive care medicine.急性肾损伤患者 ICU 中预防和处理的 ATS/ERS/ESICM/SCCM/SRLF 专家声明:重症加强治疗医学国际共识会议
Am J Respir Crit Care Med. 2010 May 15;181(10):1128-55. doi: 10.1164/rccm.200711-1664ST.
3
连续肾脏替代治疗期间舒巴坦-杜洛巴坦清除率的评估,以指导给药建议。
Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0167423. doi: 10.1128/aac.01674-23. Epub 2024 Dec 10.
4
Inborn errors of metabolism in neonates and pediatrics on varying dialysis modalities: a systematic review and meta-analysis.新生儿及儿科不同透析方式下的先天性代谢缺陷:一项系统评价与荟萃分析
Pediatr Nephrol. 2024 Nov 11. doi: 10.1007/s00467-024-06547-7.
5
Iron as an emerging therapeutic target in critically ill patients.铁作为危重症患者的一个新兴治疗靶点。
Crit Care. 2023 Dec 4;27(1):475. doi: 10.1186/s13054-023-04759-1.
6
Haemodynamic predisposition to acute kidney injury: Shadow and light!急性肾损伤的血流动力学易感性:阴影与光明!
J Anaesthesiol Clin Pharmacol. 2022 Jul-Sep;38(3):353-359. doi: 10.4103/joacp.JOACP_547_20. Epub 2022 Oct 13.
7
Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.体外膜肺氧合患者中哌拉西林他唑巴坦的群体药代动力学和剂量优化及肾替代治疗的影响。
Microbiol Spectr. 2021 Dec 22;9(3):e0063321. doi: 10.1128/Spectrum.00633-21.
8
Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy.将头孢吡肟群体药代动力学应用于接受连续肾脏替代治疗的危重症患者。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0161121. doi: 10.1128/AAC.01611-21. Epub 2021 Oct 18.
9
The Efficacy of Renal Replacement Therapy for Rewarming of Patients in Severe Accidental Hypothermia-Systematic Review of the Literature.肾脏替代疗法对严重意外低体温患者复温效果的系统评价——文献综述。
Int J Environ Res Public Health. 2021 Sep 13;18(18):9638. doi: 10.3390/ijerph18189638.
10
Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.头孢吡肟群体药代动力学及连续性肾脏替代治疗危重症患者的目标达成情况。
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00144-21.
Transient azotaemia is associated with a high risk of death in hospitalized patients.
一过性氮质血症与住院患者的高死亡率相关。
Nephrol Dial Transplant. 2010 Jun;25(6):1833-9. doi: 10.1093/ndt/gfp624. Epub 2010 Jan 6.
4
Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM.在重症监护病房预防急性肾损伤和保护肾功能。肾脏病学工作组,ESICM 的专家意见。
Intensive Care Med. 2010 Mar;36(3):392-411. doi: 10.1007/s00134-009-1678-y.
5
Intensity of continuous renal-replacement therapy in critically ill patients.危重症患者持续肾脏替代治疗的强度
N Engl J Med. 2009 Oct 22;361(17):1627-38. doi: 10.1056/NEJMoa0902413.
6
Discontinuation of continuous renal replacement therapy: a post hoc analysis of a prospective multicenter observational study.持续肾脏替代治疗的终止:一项前瞻性多中心观察性研究的事后分析
Crit Care Med. 2009 Sep;37(9):2576-82. doi: 10.1097/CCM.0b013e3181a38241.
7
Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery.尿胱抑素C作为成人胸心外科手术后急性肾损伤的早期生物标志物。
Kidney Int. 2008 Oct;74(8):1059-69. doi: 10.1038/ki.2008.341. Epub 2008 Jul 23.
8
Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients.心脏重症监护患者中药代动力学和药效学的临床相关性
Clin Pharmacokinet. 2008;47(7):449-62. doi: 10.2165/00003088-200847070-00002.
9
Intensity of renal support in critically ill patients with acute kidney injury.急性肾损伤危重症患者的肾脏支持强度
N Engl J Med. 2008 Jul 3;359(1):7-20. doi: 10.1056/NEJMoa0802639. Epub 2008 May 20.
10
Biomarkers for the diagnosis of acute kidney injury.用于诊断急性肾损伤的生物标志物。
Curr Opin Nephrol Hypertens. 2007 Nov;16(6):557-64. doi: 10.1097/MNH.0b013e3282f08745.